Latest News and Press Releases

WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug...

WALTHAM, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of data from the ENGOT-OV16/NOVA trial...

WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...

WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences....

WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S....

Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...

Collaboration enables the clinical development of niraparib in China by Zai Lab TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs...

WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...

Phase 3 results from ENGOT-OV16/NOVA trial of niraparib accepted for oral presentation during Presidential Symposium and inclusion in ESMO Press ProgrammeTESARO to webcast Investor and Analyst...

WALTHAM, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences....